Dune Medical Devices has completed the first of a two-stage $21 million equity financing. The initial closing was completed for $14 million, with a second tranche of $7 million to be completed by October 2014. The financing provides the necessary resources to expand the sales and marketing efforts for Dune’s first product, the MarginProbe System for breast cancer surgery patients. Participating in this financing were both previous and new investors, including the Kraft Group and Canepa Advanced Healthcare Fund, among others. The MarginProbe System, which received Pre-Market Approval from the FDA early last year, enables real-time detection of cancer at the surface of excised tissue specimens during surgery for breast cancer. Dune Medical Devices last raised a $7.7 million financing round in May 2010.